Maintenance Therapy with Revlimid Slows Myeloma Progression (06/03/2010)
Maintenance therapy with RevlimidÒ (lenalidomide) slowed disease progression by 54% among patients with multiple myeloma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Interim results of this Phase III study will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (03/24/2010)
Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology.

Complete Remission Predicts for Long Survival in Multiple Myeloma (03/22/2010)
Achieving a complete remission was the dominant prognostic factor for long survival in patients with multiple myeloma, according to a large retrospective review published in Bone Marrow Transplantation.

Benefit of Velcade on Myeloma Survival Added to Prescribing Information (03/05/2010)
The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients with previously untreated multiple myeloma.

Addition of Velcade® and Revlimid® to Autologous Stem Cell Transplantation Produces Promising Results in Older Patients with Multiple Myeloma (01/07/2010)
In a Phase II clinical trial, treatment of older multiple myeloma patients with Velcade® (bortezomib) induction therapy, reduced-intensity tandem autologous stem cell transplantation, and Revlimid® (lenalidomide) consolidation-maintenance therapy produced promising response rates. These results were published in the Journal of Clinical Oncology.

Velcade® Improves Response Rate After High-dose Melphalan for Myeloma (12/21/2009)
Among patients who have received high-dose melphalan and an autologous stem cell transplant for initial treatment of multiple myeloma, Velcade® (bortezomib) appears to improve treatment response rates. These results were presented at the 2009 meeting of the American Society of Hematology (ASH).

Recurrent

Stage I/Smoldering Myeloma

Stages II-III

Maintenance Therapy with Revlimid Slows Myeloma Progression (06/03/2010)
Maintenance therapy with RevlimidÒ (lenalidomide) slowed disease progression by 54% among patients with multiple myeloma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Interim results of this Phase III study will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.